Startup heart drug developer MyoKardia lands $38M Third Rock investment

James Spudich.

Third Rock Ventures is backing an all-star lineup of cardiovascular researchers with a $38 million Series A round to discover and develop drugs aimed at key genetic heart mutations. MyoKardia Inc., which will operate from South San Francisco lab space next to fellow Third Rock startup Global Blood Therapeutics Inc., is aimed at a putting together pipeline of small-molecule drugs that initially will treat hypertrophic anddilated cardiomyopathy.